Head-to-head · Stock vs Stock
Gilead Sciences vs Bristol-Myers Squibb Company
vs
GILD vs BMY: the verdict
How GILD and BMY compare today, and what CleaRank Financial AI makes of it.
The verdict
CleaRank Financial AI favours
BMY
GILD
BMY
64/100
AI score
70/100
+44.6%
1-year change
+32.9%
36.5%
Volatility (30d, yearly)
36.5%
64.2
RSI (14-day)
53.7
n/m
P/E ratio
13.9x
1.90%
Dividend yield
4.00%
The verdict
Bristol-Myers Squibb Company (BMY) comes out ahead on CleaRank's model, scoring 70/100 (Buy) against 64/100 (Buy) for Gilead Sciences (GILD). The widest gap is valuation: for BMY, the P/E of 13.78 is 56.8% below the sector median (a discount to peers) and the P/S of 2.54 is 25.3% below the sector median. For GILD, the company has no meaningful P/E because it lost money and the P/S of 6.68 is 96.5% above the sector median.
Key difference
Profitability also favours BMY: the net margin is 18.47% and return on equity of 44.01% is above the sector median. For GILD, the net margin is -12.46%, return on equity of -22.45% is below the sector median and debt-to-equity is 2.02.
Outlook
GILD's uptrend holds while it stays above its 50-day average at $153.04 and its 200-day at $140.96. BMY sits between its 50-day average at $62.26 and its 200-day at $60.18.
Price, side by side
Both prices start at 0% on the first day of the period you pick, so the moves compare directly.
Rebased price
-5%0%+5%+10%+15%+13%+6.2%
Nov '26
-10%0%+10%+20%+30%+26%-1.3%
Sep '26Oct '26Nov '26
-10%0%+10%+20%+30%+27%+11%
Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
0%+10%+20%+30%+40%+45%+33%
Dec '25Feb '26Apr '26Jul '26Sep '26Nov '26
0%+50%+100%+114%+24%
Oct '24Mar '25Aug '25Jan '26Jun '26Nov '26
Over 1 year: GILD gained 44.6% and BMY gained 32.9%, a gap of 11.7 points in GILD's favour.
Valuation and profitability
What each costs relative to its earnings and sales, and how much of its revenue it keeps.
Side by side
Valuation
Lower multiples mean you pay less for each dollar of earnings or sales.
GILD
BMY
$211.9B
Market cap
$128.4B
n/m
P/E ratio
13.9x
6.8x
Price / sales
2.6x
16.1x
Price / book
5.4x
15.6x
EV / EBITDA
8.7x
Profitability
How much of each dollar of revenue becomes profit, and how hard the capital works.
GILD
BMY
+10.2%
Revenue growth (quarter, y/y)
+5.7%
-12.5%
Net margin
18.5%
-22.4%
Return on equity
44.0%
13.5%
Return on assets
10.9%
2.02
Debt / equity
1.91
On valuation
BMY's P/E is at a discount to peers when set against the Healthcare median of 31.9. GILD carries the richer sales multiple, at 6.68 times compared with 2.54 for BMY. Size also favors GILD, which is worth $207.0B versus $127.0B for BMY.
On profitability
Measured by net margin, BMY keeps far more of each sale as profit: 18.47% against -12.46% for GILD. Return on equity tells the same story, with BMY at 44.01% and GILD at -22.45%. On revenue, GILD grew 10.20% in the latest quarter year on year, while BMY grew 5.74%. For income investors, GILD's trailing dividend yield is 1.94% and BMY's is 4.04%.
Earnings reality check
GILD
GILD beat the estimate in 8 of its last 8 reports (latest Oct '26); the shares fell in the first session after 3 of those beats.
Surprise
Next session
Apr '25Oct '25May '26Oct '26
BMY
BMY beat the estimate in 8 of its last 8 reports (latest Oct '26); the shares fell in the first session after 2 of those beats.
Surprise
Next session
Apr '25Oct '25Apr '26Oct '26
Momentum and sentiment
The indicators behind each AI score, side by side.
Indicators side by side
GILD
BMY
64/100
AI score
70/100
64.2
RSI (14-day)
53.7
+11.0%
Price against 50-day average
+1.0%
+20.9%
Price against 200-day average
+4.3%
Technicals
GILD is in an uptrend, trading 10.96% above its 50-day average and 20.93% above its 200-day average. Its 14-day RSI is 64.2, in the bullish zone, with the MACD line positive. BMY is in an uptrend, trading 1.00% above its 50-day average and 4.28% above its 200-day average. Its 14-day RSI is 53.7, in the neutral zone, with the MACD line positive. GILD sits higher in its 52-week range, at 85% against 72% for BMY.
Sentiment
Of the 28 analysts covering GILD, 22 rate it buy, 5 hold and 1 sell; their median target is $175.00, 4.4% above the price. Of the 28 analysts covering BMY, 10 rate it buy, 17 hold and 1 sell; their median target is $65.50, 5.4% above the price.
Risk and practical tips
How much each moves, how much return each has paid for that risk, and what to watch if you hold either.
Risk measures
GILD
BMY
36.5%
Volatility (30d, yearly)
36.5%
0.37
Beta against the S&P 500
0.19
1.26
Sharpe ratio
0.33
Risk
They move about the same on a typical day, 2.06% for GILD and 2.14% for BMY. Against the S&P 500, GILD has a beta of 0.37 and BMY 0.19. Their worst falls in the price history were 28.7% for GILD (January 2018 to December 2020) and 46.2% for BMY (December 2022 to May 2024). The measures disagree, so neither is clearly the riskier of the two.
ProTips
- For GILD, watch the 52-week high at $176.58 above the price and the 20-day EMA at $161.53 below it.
GILD vs BMY: long-term scenarios
Simulated paths from each price history. A range of outcomes, not a forecast.
Simulated growth of $10,000
$10K$20K$30K$40K$50K$49.5K$36.4K$18.4K$13.9K
202620282030203220342035
GILD
BMY
$6,875
Downside, 2035 (10th)
$5,311
$18,440
Base case, 2035 (median)
$13,900
$49,460
Upside, 2035 (90th)
$36,377
In the median simulated path, $10,000 in GILD grows to about $18,400 and $10,000 in BMY grows to about $13,900 by 2035. The paths come from each asset's own volatility and capped historical trend; they are statistical outcomes, not forecasts.
GILD vs BMY: questions people ask
Answered from the figures on this page.
Frequently Asked Questions
Which is better, GILD or BMY?+
On CleaRank's model BMY scores higher, 70/100 (Buy) against 64/100 (Buy) for GILD. This describes the data on this page and is not a personal recommendation.
Which has performed better over the past year, GILD or BMY?+
GILD has done better: its price rose 35.24% over the past year, while BMY rose 33.09%.
Which pays more income, GILD or BMY?+
BMY pays the higher yield, 4.04% compared with 1.94% for GILD. Yield is the payout divided by the price, so it moves whenever either of those changes.
Which is riskier, GILD or BMY?+
Neither is clearly riskier: the measures point different ways. Average daily move: 2.06% for GILD, 2.14% for BMY. Beta against the S&P 500: 0.37 for GILD, 0.19 for BMY. Worst fall in the price history: 28.7% for GILD, 46.2% for BMY.
Which has stronger momentum right now, GILD or BMY?+
The MACD line is positive for both stocks. Readings above 70 or below 30 point to stretched momentum.
Which is the bigger company, GILD or BMY?+
GILD is the larger company by market value: $207.0B against $127.0B for BMY.
What do analysts say about GILD and BMY?+
GILD has 22 buy ratings out of 28, and its median target is 4.4% above the price. BMY has 10 buy ratings out of 28, and its median target is 5.4% above the price.
How would $10,000 have grown in GILD or BMY?+
Invested in December 2016, $10,000 would be worth $32,524 today in GILD and $15,835 in BMY.
Which is closer to its 52-week high, GILD or BMY?+
GILD sits closer to its 52-week high of $176.58: the price is 5.03% below it. BMY is 9.47% below its own 52-week high of $68.64.